Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The initial product GLP-1 (137) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (736) amide and GLP-1 (737)
Retatrutide is administered as a once-weekly subcutaneous injection and is currently under Phase 3 clinical development for obesity and type 2 diabetes
Microarray and RNA-seq data generated in this study have been deposited in the Gene Expression Omnibus under accession code GSE184055 and GSE184261, respectively
Amgen, Viking Therapeutics, Boehringer Ingelheim, Zealand Pharma, and Pfizer are also important watchlist companies
US$ 22.38
US$ 22.71
US$ 21.49
US$ 24.89
US$ 24.80
US$ 25.27
US$ 28.28
US$ 27.51
US$ 27.19
US$ 27.00
US$ 26.90
US$ 26.57
US$ 20.28
